M
Marcin Kurzyna
Researcher at Medical University of Warsaw
Publications - 165
Citations - 8139
Marcin Kurzyna is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 28, co-authored 139 publications receiving 7305 citations.
Papers
More filters
Journal ArticleDOI
Sildenafil citrate therapy for pulmonary arterial hypertension.
Nazzareno Galiè,Hossein Ardeschir Ghofrani,Adam Torbicki,Robyn J. Barst,Lewis J. Rubin,David B. Badesch,Thomas R. Fleming,Tamiza Parpia,Gary Burgess,Angelo Branzi,Friedrich Grimminger,Marcin Kurzyna,Gérald Simonneau +12 more
TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.
Journal ArticleDOI
Definitions and diagnosis of pulmonary hypertension.
Marius M. Hoeper,Harm Jan Bogaard,Robin Condliffe,Robert P. Frantz,Dinesh Khanna,Marcin Kurzyna,David Langleben,Alessandra Manes,Toru Satoh,Fernando Torres,Martin R. Wilkins,David B. Badesch +11 more
TL;DR: Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing has a higher predictive value than echocardiography alone.
Journal ArticleDOI
Definitions and diagnosis of pulmonary hypertension
Marius M. Hoeper,Harm Jan Bogaard,Robin Condliffe,Robert P. Frantz,Dinesh Khanna,Marcin Kurzyna,David Langleben,Alessandra Manes,Toru Satoh,Fernando Torres,Martin R. Wilkins,David B. Badesch +11 more
TL;DR: Pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) 15 mm Hg and a pulmonary vascular resistance > 3 Wood units as discussed by the authors.
Journal ArticleDOI
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Anna Fijałkowska,Marcin Kurzyna,Adam Torbicki,Grzegorz Szewczyk,Michał Florczyk,Piotr Pruszczyk,Monika Szturmowicz +6 more
TL;DR: A serum NT-proBNP level of > or = 1,400 pg/mL was found to be useful in identifying patients with poor long-term prognosis both in the whole studied group and in the IPAH subgroup.
Journal ArticleDOI
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Nazzareno Galiè,Alan L. Hinderliter,Adam Torbicki,Thierry Fourme,Gérald Simonneau,Tomás Pulido,Nilda Espinola-Zavaleta,Guido Rocchi,Alessandra Manes,Robert P. Frantz,Marcin Kurzyna,Sherif F. Nagueh,Robyn J. Barst,Richard N. Channick,Karl Dujardin,Andrew Kronenberg,Isabelle Leconte,Maurizio Rainisio,Lewis J. Rubin +18 more
TL;DR: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.